Skip to main content
Top
Published in: Langenbeck's Archives of Surgery 2/2017

01-03-2017 | ORIGINAL ARTICLE

The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage

Authors: Augustas Beiša, Mindaugas Kvietkauskas, Virgilijus Beiša, Mindaugas Stoškus, Elvyra Ostanevičiūtė, Eugenijus Jasiūnas, Laimonas Griškevičius, Kęstutis Strupas

Published in: Langenbeck's Archives of Surgery | Issue 2/2017

Login to get access

Abstract

Purpose

This study aims to determine the utility of the Bethesda category and its association with BRAF mutation in prediction of the papillary thyroid cancer (PTC) stage.

Methods

A prospective study analyzed patients who had ultrasound-suspicious thyroid nodules, underwent FNA and cytological examination, and were classified according to the Bethesda system. Patients from Undetermined Significance Or Follicular Lesion Of Undetermined Significance (AUS/FLUS), Follicular Neoplasm or Suspicious for a Follicular Neoplasm (FN/SFN), Suspicious for Malignant Cells (SMC), and Positive for Malignant Cells (PMC) groups were examined for the BRAF mutation and had a thyroid surgery. Demographical and histological features and stage of the disease were evaluated for PTC patients in accordance with the Bethesda category and its association with BRAF mutation.

Results

Three hundred eight of all patients underwent operation. One hundred forty-three (46.4%) of them were diagnosed with PTC. In 14 (9.8%) PTC cases, FNA biopsies were classified as AUS/FLUS, 23 (16.1%) as FN/SFN, 41 (28.7%) as SMC, and 65 (45.5%) as PMC. I–II stages of PTC were diagnosed for 88 (61.5%) patients and III–IVA for 55 (38.5%). Patients from the SMC and PMC groups had larger tumors, higher incidence of lymph node metastases, classical PTC type, B-type Raf (BRAF) positive, and III–IVA stage cancer, than patients from the AUS/FLUS and FN/SFN groups. When comparing 27 (18.9%) BRAF-negative patients from the AUS/FLUS and FN/SFN groups with 116 (81.1%) BRAF-negative patients from the SMC and PMC groups and all BRAF-positive patients, the prediction of more aggressive histological features and stage was slightly improved.

Conclusions

Higher Bethesda categories are associated with higher stages of PTC. Association of the Bethesda category with BRAF mutation can slightly improve the value of stage prediction.
Literature
1.
go back to reference Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154(6):787–803. doi:10.1530/eje.1.02158 CrossRefPubMed Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154(6):787–803. doi:10.​1530/​eje.​1.​02158 CrossRefPubMed
3.
go back to reference Lukas J, Drabek J, Lukas D, Dusek L, Gatek J (2013) The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 157:266–275. doi:10.5507/bp.2012.086 PubMed Lukas J, Drabek J, Lukas D, Dusek L, Gatek J (2013) The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 157:266–275. doi:10.​5507/​bp.​2012.​086 PubMed
5.
go back to reference Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, Lee JH, Lee KH, Park JT (2015) VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Arch 467:155–168. doi:10.1007/s00428-015-1773-0 CrossRefPubMed Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, Lee JH, Lee KH, Park JT (2015) VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Arch 467:155–168. doi:10.​1007/​s00428-015-1773-0 CrossRefPubMed
6.
go back to reference Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. doi:10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. doi:10.​1089/​thy.​2015.​0020 CrossRefPubMedPubMedCentral
7.
go back to reference Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L, Strupas K (2016) The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer. Endokrynol Pol 67:35–40. doi:10.5603/EP.2016.0005 CrossRefPubMed Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L, Strupas K (2016) The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer. Endokrynol Pol 67:35–40. doi:10.​5603/​EP.​2016.​0005 CrossRefPubMed
9.
go back to reference Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM (2015) Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: new insights. Cancer Cytopathol 123:593–602. doi:10.1002/cncy.21586 CrossRefPubMed Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM (2015) Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: new insights. Cancer Cytopathol 123:593–602. doi:10.​1002/​cncy.​21586 CrossRefPubMed
12.
go back to reference Fnais N, Soobiah C, Al-Qahtani K, Hamid JS, Perrier L, Straus SE, Tricco AC (2015) Diagnostic value of fine needle aspiration BRAF (V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. Hum Pathol 46:1443–1454. doi:10.1016/j.humpath.2015.06.001 CrossRefPubMed Fnais N, Soobiah C, Al-Qahtani K, Hamid JS, Perrier L, Straus SE, Tricco AC (2015) Diagnostic value of fine needle aspiration BRAF (V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. Hum Pathol 46:1443–1454. doi:10.​1016/​j.​humpath.​2015.​06.​001 CrossRefPubMed
14.
go back to reference Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A et al. (2010) AJCC Cancer staging manual. 7th ed. Springer-Verlag New York. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A et al. (2010) AJCC Cancer staging manual. 7th ed. Springer-Verlag New York.
15.
go back to reference Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS (2015) Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery 158:1500–1511. doi:10.1016/j.surg.2015.05.016 CrossRefPubMed Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS (2015) Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery 158:1500–1511. doi:10.​1016/​j.​surg.​2015.​05.​016 CrossRefPubMed
17.
go back to reference Meng Z, Lu J, Wu H, Zhao Y, Luo Y, Gao J, Zhu Q, Jiang Y, Li W, Liang Z (2015) Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens. Tumour Biol 4 Meng Z, Lu J, Wu H, Zhao Y, Luo Y, Gao J, Zhu Q, Jiang Y, Li W, Liang Z (2015) Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens. Tumour Biol 4
18.
21.
go back to reference Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN (2009) Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092–2098. doi:10.1210/jc.2009-0247 CrossRefPubMed Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN (2009) Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092–2098. doi:10.​1210/​jc.​2009-0247 CrossRefPubMed
22.
go back to reference VanderLaan PA, Marqusee E, Krane JF (2012) Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda system for reporting thyroid cytopathology. Cancer Cytopathol 120:245–253. doi:10.1002/cncy.21189 CrossRefPubMedPubMedCentral VanderLaan PA, Marqusee E, Krane JF (2012) Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda system for reporting thyroid cytopathology. Cancer Cytopathol 120:245–253. doi:10.​1002/​cncy.​21189 CrossRefPubMedPubMedCentral
23.
go back to reference Galuppini F, Pennelli G, Vianello F, Censi S, Zambonin L, Watutantrige-Fernando S, Manso J, Nacamulli D, Lora O, Pelizzo MR, Rugge M, Barollo S, Mian C (2016) BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. Clin Chem Lab Med 54(9):1531–1539. doi:10.1515/cclm-2015-0218 PubMed Galuppini F, Pennelli G, Vianello F, Censi S, Zambonin L, Watutantrige-Fernando S, Manso J, Nacamulli D, Lora O, Pelizzo MR, Rugge M, Barollo S, Mian C (2016) BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. Clin Chem Lab Med 54(9):1531–1539. doi:10.​1515/​cclm-2015-0218 PubMed
26.
go back to reference Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R (2009) BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27(18):2977–2982. doi:10.1200/jco.2008.20.1426 CrossRefPubMedPubMedCentral Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R (2009) BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27(18):2977–2982. doi:10.​1200/​jco.​2008.​20.​1426 CrossRefPubMedPubMedCentral
28.
go back to reference Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56(1):89–97CrossRefPubMed Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56(1):89–97CrossRefPubMed
Metadata
Title
The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage
Authors
Augustas Beiša
Mindaugas Kvietkauskas
Virgilijus Beiša
Mindaugas Stoškus
Elvyra Ostanevičiūtė
Eugenijus Jasiūnas
Laimonas Griškevičius
Kęstutis Strupas
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Langenbeck's Archives of Surgery / Issue 2/2017
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-017-1560-2

Other articles of this Issue 2/2017

Langenbeck's Archives of Surgery 2/2017 Go to the issue